Please use this identifier to cite or link to this item:
|Title:||Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression||Authors:||Zeng, J.
|Issue Date:||1-May-2012||Citation:||Zeng, J., Shahbazi, M., Wu, C., Toh, H.C., Wang, S. (2012-05-01). Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. Journal of Immunology 188 (9) : 4297-4304. ScholarBank@NUS Repository. https://doi.org/10.4049/jimmunol.1102343||Abstract:||Human embryonic stem cell-derived dendritic cells (hESC-DCs) may potentially provide a platform to generate "off-the-shelf" therapeutic cancer vaccines. To apply hESC-DCs for cancer immunotherapy in a semiallogeneic setting, it is crucial for these cells to "jump-start" adaptive antitumor immunity before their elimination by host alloreaction. In this study, we investigated whether CD1d upregulation in hESC-DCs may exploit invariant NKT (iNKT) cell adjuvant activity and boost antitumor immunity. Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upreg-ulated CD1d was functional in presenting α-galactosylceramide for iNKT cell expansion. Pulsed with melanoma Ag recognized by T cell 1 peptide, the CD1d-overexpressing hESC-DCs displayed enhanced capability to prime CD8 + T cells without relying on α-galactosylceramide loading. Blocking the CD1d with Ab reduced the immunogenicity, suggesting the importance of hESC-DC and iNKT cell interaction in this context. The CD1d-overexpressing hESC-DCs also induced a proinflammatory cytokine profile that may favor the T cell priming. Moreover, a similar immunostimulatory effect was observed when the CD1d upregulation strategy was applied in human monocyte-derived dendritic cells. Therefore, our study suggests that the upregulation of CD1d in hESC-DCs provides a novel strategy to enhance their immunogenicity. This approach holds potential for advancing the application of hESC-DCs into human cancer immunotherapy. © 2012 by The American Association of Immunologists, Inc.||Source Title:||Journal of Immunology||URI:||http://scholarbank.nus.edu.sg/handle/10635/100584||ISSN:||00221767||DOI:||10.4049/jimmunol.1102343|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 1, 2022
WEB OF SCIENCETM
checked on Sep 23, 2022
checked on Sep 22, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.